louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06633809: Therapy Evaluation in Patients With Minor Stroke and Large Vessel Occlusion
Official title: Therapy Evaluation in Patients With Minor Stroke and Large Vessel Occlusion: A Prospective Multicenter Registry Study
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Stroke, Acute
Cerebrovascular Disorders
Brain Diseases
Central Nervous System Diseases
Vascular Diseases
Brain Infarction
Nervous System Diseases
Keywords: stroke
Mechanical thrombectomy
Proximal intracranial arterial occlusions
Large vessel occlusion
acute neurological deterioration
Outcome
Lead sponsor: Sir Run Run Shaw Hospital
Sponsor class: OTHER
First posted: 2024-10-09
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Acute ischemic stroke patients with minor stroke (NIHSS 0-5) and large artery occlusion.

Brief summary: This multicenter registry study, which record the therapy strategy and follows up these acute ischemic stroke (AIS) patients with low NIHSS and large vessel occlusion (LVO), is intended to provide the important data for therapy evaluation and prognostic prediction of the LVO patients with low NIHSS.

Detailed description: It was reported that about two third of the stoke patients might present with minor or mild stroke symptoms. 20-40% of those minor stroke patients had large vessel occlusion (LVO). AIS patients with LVO and low NIHSS are common and has been associated with early neurological deterioration and worse outcomes. Until now, the best therapy strategy for the acute stoke patients with minor stroke and large vessel occlusion is unknown. Thus, we sought to (1) explore the potential predictors of acute neurological deterioration and 90-day clinical outcome; (2) and evaluate the best therapy strategy.

Eligibility criteria: Inclusion Criteria:

1. Aged 18 years or older
2. Acute ischemic stroke patients of NIHSS 0-5 with 24 hours after onset
3. Proximal intracranial artery occlusion on NCCT/CTA or MRI/MRA showing occlusion of the intracranial ICA, M1, or proximal M2 vessel
4. Baseline ASPECTS ≥6 or infarct Core Volume of \< 70 on NCCT/DWI/CTP
5. Pre-mRS≤1

Exclusion Criteria:

1. Any sign of intracranial hemorrhage on baseline CT/MR;
2. Seizures at stroke onset
3. Baseline blood glucose of \<2.78 mmol or \>22.20 mmol, or platelet count \< 100,000/uL or serum creatinine levels \> 3.0 mg/dL
4. Participation in any investigational study in the previous 30 days

Primary outcomes:
measure: modified Rankin Scale at 90 days
timeFrame: 90 days
measure: acute neurological deterioration
timeFrame: 24 hours
Secondary outcomes:
measure: Incidence of symptomatic intracerebral hemorrhage
timeFrame: 2-3 days
measure: patients with good outcome comparing the two treatment groups
timeFrame: 90 days
Other outcomes:
Locations:
city: Hangzhou
country: China
facility: Sir Run Run Shaw Hospital
state: Zhejiang
Study officials:
References:
Clinical trial NCT01491009: Comparison of Remifentanil With Dexmedetomidine or Midazolam in Regards of Sedation Effectivity and Postoperative Cognitive Functions in Cystoscopies
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Postoperative Cognitive Functions
Keywords: Dexmedetomidine
midazolam
remifentanil
mini-mental state examination
monitored anaesthesia care
cystoscopy
sedation
Lead sponsor: Gazi University
Sponsor class: OTHER
First posted: 2011-12-13
Enrollment: 40
Sex: ALL
Minimum age (years): 20
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The aim of the study was to compare the effects of remifentanil-dexmedetomidine and remifentanil-midazolam with mini-mental state examination (MMSE) in monitored anesthesia care (MAC) patients undergoing cystoscopy.

Detailed description: Forty patients undergoing cystoscopy receiving remifentanil infusion of 0.05 microgram per kg-1 min-1 were randomized into two groups: Either dexmedetomidine 1 microgram per kg -1 (GroupD) or midazolam 0.2 mg kg-1h-1 (GroupM) were administered intravenously for the first 10 minutes. Subsequently anesthesia was maintained by using the bispectral index(BIS) as a continuous infusion of dexmedetomidine 0.2-0.7 microgram per kg-1h-1 or midazolam 0.05-0.15 mgkg-1h-1. Heart rate, mean arterial pressure, MMSE, sedation and the patient's and surgeon's satisfaction were determined.

Eligibility criteria: Inclusion Criteria:

* patients with indication of cystoscopy must be able to have sedation

Exclusion Criteria:

* hypersensitivity to drugs used
* morbid obesity
* coronary disease
* diabetes mellitus and other endocrinologic diseases
* pregnancy
* psychomotor diseases

Primary outcomes:
measure: Degree of sedative efficiency
timeFrame: During cystoscopy procedure
measure: Degree of cognitive functions
timeFrame: Postoperative 60 minutes
Secondary outcomes:
Other outcomes:
Locations:
city: Ankara
country: Turkey
facility: Gazi University Faculty of Medicine Hospital
Study officials:
affiliation: Gazi University
name: Ayşe Arpacı, M.D.
role: PRINCIPAL_INVESTIGATOR
affiliation: Gazi University
name: Füsun Bozkırlı, M.D.
role: STUDY_DIRECTOR
References:
Clinical trial NCT05257109: Water Content in E-Liquids
Official title: Water Content In E-Liquids
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Nicotine E-Cigarette Use
Lead sponsor: Yale University
Sponsor class: OTHER
Collaborators: name: National Institute on Drug Abuse (NIDA)
First posted: 2022-02-25
Enrollment: 31
Sex: ALL
Minimum age (years): 21
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Intervention model description: Within subject design, all participants will receive all e-liquid flavors/water concentrations
Primary purpose: OTHER

Brief summary: This study looks at the effect of manipulating the water concentration of certain e-liquids on sensory perception.

Detailed description: This study looks at the effect of manipulating water concentration on e-cigarettes that contain aldehyde flavor chemicals on sensory perception. Regular e-cigarette users will be asked to complete 2 lab sessions in which they will sample 4 nicotine containing e-liquids. Each e-liquid will be sampled in four water concentration manipulations. Researchers will examine influence of flavor and water concentrations on sensory experience including appeal/liking and irritation and harshness.

Eligibility criteria: Inclusion Criteria:

* at least 21 years old
* able to read/write
* \>/= 6 mths e-cig use
* regular e-cig use (\>/= 4 days/week)
* use of flavored e-cigs
* use of nicotine containing e-cigs
* urine cotinine \>/= 200ng/ml
* no plan to quit e-cig use

Exclusion Criteria:

* breastfeeding, pregnant, trying to become pregnant
* Medical conditions that increase risk of respiratory problems among participants
* Current use of illegal substances
* Medical conditions increasing risk of respiratory problems in nonpatient populations
* Current diagnosis of an untreated psychiatric condition
* Not fully vaccinated for Coronavirus-19

Primary outcomes:
measure: Irritation/Harshness
timeFrame: immediately after intervention, up to 15 minutes
measure: Appeal Assessed Using the Labeled Hedonic Scale (LHS) Ranging From -100 to 100
timeFrame: immediately after intervention, up to 15 minutes
measure: Appeal Assessed Using the Drug Effects Questionnaire (DEQ)
timeFrame: immediately after intervention, up to 15 minutes
Secondary outcomes:
Other outcomes:
Locations:
city: New Haven
country: United States
facility: Yale School of Medicine
state: Connecticut
Study officials:
affiliation: Yale University
name: Danielle Davis, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03381209: The Effect of Sugammadex Given Based on Ideal, Actual or Adjusted Body Weight on Reversal of Rocuronium.
Official title: The Effect of Sugammadex Given Based on Ideal, Actual or Adjusted Body Weights on Reversal of Neuromuscular Blockade in Morbidly Obese Patients Undergoing Laparoscopic Bariatric Surgery
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Muscle Relaxation
Keywords: Sugammadex
morbidly obese patients
bariatric surgery
neuromuscular blockade
Lead sponsor: Ain Shams University
Sponsor class: OTHER
First posted: 2017-12-21
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: The aim of this study is compare the reversal of rocuronium induced neuromuscular blockade in morbidly obese patients using three doses of sugammadex; based on ideal body weight, adjusted body weight, and actual body weight.

Detailed description: The aim of this study is compare the reversal of rocuronium induced neuromuscular blockade in morbidly obese patients using three doses of sugammadex; based on ideal body weight, adjusted body weight, and actual body weight. Reversal Time: time from administration of Sugammadex to train of four (TOF) ratio ≥ 0.9 will be used as primary outcome.

Time need for extubation (time from administration of sugammadex to extubation), and duration of stay in post anesthesia care unit (PACU), will be used as secondary outcome.

Eligibility criteria: Inclusion Criteria:

* patients older than 18 years and under 45 years,
* body mass index ≥ 40 kg/m2, with indication of bariatric surgery

Exclusion Criteria:

* Patients with comorbid including: neuromuscular disease, renal impairment, and patients with difficult airway were excluded from this study.

Primary outcomes:
measure: Reversal Time
timeFrame: 5 minutes after sugammadex administration
Secondary outcomes:
measure: duration of stay in PACU
timeFrame: 60 minutes after admission to the PACU
measure: Time need for Extubation
timeFrame: 10 minutes after sugammadex administration
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Faculty of Medicine, Ain Shams University
Study officials:
affiliation: Anesthesiology department, Faculty of Medicine, Ain Shams University
name: Walid Nofal, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04783909: Refractive Outcomes After Cataract Surgery in Eyes With Pseudoexfoliation Syndrome
Official title: Refractive Outcomes of Phacoemulsification Cataract Surgery in Eyes With Pseudoexfoliation Syndrome
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Refractive Errors
Cataract
Keywords: pseudoexfoliation
phacoemulsification cataract surgery
IOL power calculation formulas
Lead sponsor: Medical University of Lublin
Sponsor class: OTHER
First posted: 2021-03-05
Enrollment: 80
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients above 18 yo with senile cataract with/without PEX without coexisting ocular pathologies

Brief summary: To evaluate the refractive outcomes of cataract surgery in PEX syndrome and determine which of the commonly used IOL formulas (SRK/T, Barrett Universal II and Hill-RBF) is the best in predicting postoperative refractive outcomes in PEX.

Detailed description: The primary outcome measure was to compare refractive outcomes (MAE, MedAE, percentage of eyes within certain range of prediction error) in PEX and control eyes. The secondary outcome measure was to determine whether any of IOL power prediction formulas (SRK/T, Barrett Universal II and Hill-RBF) is more precise for these challenging eyes.

Eligibility criteria: Inclusion Criteria:

* senile cataract with/without PEX

Exclusion Criteria:

* corneal pathology
* glaucoma,
* corneal astigmatism greater than 2.0 diopters (D),
* previous eye surgery or subjects with decreased vision due to other reasons than cataract (e.g., exudative age-related macular degeneration (AMD), proliferative diabetic retinopathy, inflammatory eye diseases),
* intraoperative complications,
* postoperative corrected distance visual acuity (CDVA) worse than 20/40,
* axial length below 21 mm and above 25 mm,
* dense cataracts or poor fixation requiring ultrasound biometry
* eyes with manifest iridophacodonesis and those in which a capsular tension ring was inserted

Primary outcomes:
measure: To compare refractive outcomes in PEX and control eyes.
timeFrame: 3 months
Secondary outcomes:
measure: To determine whether any of IOL power prediction formulas is more precise for these challenging eyes.
timeFrame: 3 months
Other outcomes:
Locations:
Study officials:
affiliation: Medical University in Lublin
name: Tomasz Żarnowski, MD, PhD, Professor
role: STUDY_CHAIR
References:
citation: Wlaz A, Kustra A, Rozegnal-Madej A, Zarnowski T. Intraocular lens power calculations in eyes with pseudoexfoliation syndrome. Sci Rep. 2021 Sep 24;11(1):19071. doi: 10.1038/s41598-021-98675-5.
Clinical trial NCT01151709: Assessment of Primary Care Providers' Knowledge and Beliefs Regarding Gout Management
Official title: Assessment of Primary Care Providers' Knowledge and Beliefs Regarding Gout Management
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Gout
Keywords: Gout
Chronic condition management
Gout management
Lead sponsor: University of Massachusetts, Worcester
Sponsor class: OTHER
Collaborators: name: Takeda
First posted: 2010-06-28
Enrollment: 838
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: Primary care practitioners, both family practice and internal medicine physicians from a nationwide sample

Brief summary: This is a questionnaire study aimed at learning about physicians' views on the treatment of Gout.

Detailed description: We seek to assess the knowledge, beliefs and reported treatment practices of primary care physicians with regard to gout.

Specifically, we will:

* Assess the knowledge and beliefs with regard to acute and chronic gout management based on published treatment recommendations.
* Characterize the individuals who have knowledge deficits in terms of age, specialty, number of patients seen with gout, and practice setting.
* Assess the reported treatment practices of primary care physicians for the acute and chronic management of gout.

Eligibility criteria: Inclusion Criteria:

* practicing primary care practitioner, either in family medicine or internal medicine,
* must be 18 years of age or older

Exclusion Criteria:

* does not meet inclusion criteria

Primary outcomes:
measure: Assess the knowledge and beliefs with regard to acute and chronic gout management based on published treatment recommendations.
timeFrame: 3 months
measure: Characterize the individuals who have knowledge deficits in terms of age, specialty, number of patients seen with gout, and practice setting.
timeFrame: 3 months
measure: Assess the reported treatment practices of primary care physicians for the acute and chronic management of gout.
timeFrame: 3 months
Secondary outcomes:
Other outcomes:
Locations:
city: Worcester
country: United States
facility: UMass Medical School
state: Massachusetts
Study officials:
affiliation: UMass Medical School
name: Leslie R Harrold, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00358007: Use of Cone Beam Kilovoltage Imaging in Patients Receiving Radiation Therapy for Head and Neck Cancer
Official title: Evaluation of Cone Beam Kilovoltage Imaging During Radiation Therapy for Tumors of the Head and Neck
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE2
Conditions: Head and Neck Neoplasms
Keywords: Kilovoltage Imaging
Cone-beam CT
CBCT
radiation therapy
head and neck neoplasms
Lead sponsor: Thomas Jefferson University
Sponsor class: OTHER
First posted: 2006-07-28
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: SUPPORTIVE_CARE

Brief summary: To evaluate the use of cone beam computed tomography in treating head and neck to hopefully reduce side effects

Detailed description: The general purpose of this study is to evaluate Kilovoltage (kv) Imaging, specifically the Cone-beam CT (CBCT) scan device, to assess the accuracy of radiation therapy treatment delivery for patients with head and neck neoplasms

Eligibility criteria: Inclusion Criteria:

* any patient receiving radiation therapy for a head and neck tumor assigned to the new Elekta Synergy Linare Accelerator

Exclusion Criteria:

* NA

Primary outcomes:
measure: Average Interfraction Shift of Patients Undergoing Radiotherapy
timeFrame: Daily prior to radiation
measure: Average Residual Error Motion of Patients Undergoing Radiotherapy
timeFrame: Daily after each radiotherapy treatment
Secondary outcomes:
Other outcomes:
Locations:
city: Philadelphia
country: United States
facility: Thomas Jefferson University
state: Pennsylvania
Study officials:
affiliation: Thomas Jefferson University
name: Pramila Rani Anne, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Den RB, Doemer A, Kubicek G, Bednarz G, Galvin JM, Keane WM, Xiao Y, Machtay M. Daily image guidance with cone-beam computed tomography for head-and-neck cancer intensity-modulated radiotherapy: a prospective study. Int J Radiat Oncol Biol Phys. 2010 Apr;76(5):1353-9. doi: 10.1016/j.ijrobp.2009.03.059. Epub 2009 Jun 18.
Clinical trial NCT01240707: Pathophysiologic Changes in the Respiratory System After Fire Smoke Inhalation
Official title: Pathophysiologic Changes in the Respiratory System After Fire Smoke Inhalation
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Bronchial Asthma
Lead sponsor: Oslo University Hospital
Sponsor class: OTHER
First posted: 2010-11-15
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: Fire smoke inhalation may contribute to intrabronchial inflammation, airway obstruction and impaired gas exchange. In this study the investigators will examine if the scope of inhalation injury can be assessed soon after hospital admission based on clinical markers, biochemical markers, Peak Expiratory Flow (PEF), spirometry and bronchoscopy. At 6 months a lung function test and metacholine test will be performed to examine whether patients have developed increased bronchial hyperreactivity (asthma) or not after the initial fire smoke exposure.

Detailed description: Fire smoke inhalation may contribute to intrabronchial inflammation, airway obstruction and impaired gas exchange. The scope of injury in fire smoke victims ranges from cough and minor airway irritation to severe respiratory failure and long term mechanical ventilation in the Intensive Care Unit. Some patients with high HbCO-levels are also treated with hyperbaric oxygen therapy.

In this study the investigators will examine if the scope of inhalation injury can be assessed soon after admission based on clinical markers, biochemical markers, Peak Expiratory Flow (PEF), spirometry and bronchoscopy. The clinical effect of fiberoptic bronchoscopy after severe smoke inhalation will also be examined. At 6 months a lung function test and metacholine test will be performed to examine whether they have developed asthma/increased bronchial hyperreactivity or not after the initial fire smoke exposure. Lab staff (flowcytometer and cytokine analysis) are unaware of patient identity and whether the patient is a smoke-exposed patient or a healthy volunteer in the control group of non-exposed persons.

Eligibility criteria: Inclusion Criteria:

* fire smoke exposed patient
* \> 18 years of age
* admitted to hospital

Exclusion Criteria:

* \< 18 years of ager
* trauma patient

Control group (healthy volunteers/hospital staff):

* \> 18 years of age
* non-smoker
* no exposure to fire smoke

Primary outcomes:
measure: Positive metacholine test (bronchial hyperreactivity).
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Oslo
country: Norway
facility: Oslo University Hospital - Ulleval
Study officials:
affiliation: Oslo University Hospital - Ulleval, Norway
name: Espen R Nakstad, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Ullevaal University Hospital
name: Helge Opdahl, MD, PhD
role: STUDY_DIRECTOR
References:
Clinical trial NCT00763607: Retrospective Study Evaluating IGF1R And p95HER2 as Prognostic Factors in Non Small Cell Lung Cancer (NSCLC)
Official title: Retrospective Study Evaluating IGF1R And p95HER2 as Prognostic Factors in Radically Resected Non Small Cell Lung Cancer
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Non Small Cell Lung Cancer
Keywords: non small cell lung cancer patients
Lead sponsor: Istituto Clinico Humanitas
Sponsor class: OTHER
First posted: 2008-10-01
Enrollment: 454
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Radically resected non small cell lung cancer patients

Brief summary: Aim of the study is to evaluated the role of IGF1R and p95HER2 on prognosis in radically resected non small cell lung cancer patients

The primary objective is to correlate the expression of IGF1R and p95HER2 with survival.


Eligibility criteria: Inclusion Criteria:

* Radically resected non small cell lung cancer patients with tumor tissue available

Exclusion Criteria:

* Tumor tissue not available
* Clinical data not available

Primary outcomes:
measure: Association of different biomarkers with survival
timeFrame: At the end of enrollment
Secondary outcomes:
measure: Association of a specific biomarker with patient's characteristics
timeFrame: At the end of enrollment
Other outcomes:
Locations:
city: Rozzano
country: Italy
facility: Istituto Clinco Humanitas
state: Milan
Study officials:
affiliation: Istituto Clinico Humanitas
name: Armando Santoro, MD
role: PRINCIPAL_INVESTIGATOR
References: